- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01948440
ASI-MV Solutions: A Tailored Program for Substance Abusers in Early Recovery
20 de setembro de 2013 atualizado por: Emil Chiauzzi, Inflexxion, Inc.
Making referrals to medical and psychosocial services for substance abuse clients has proven difficult due to lack of access to services, inadequate counselor knowledge, and lack of motivation and skills among clients.
Inflexxion is proposing the development of ASI-MV Solutions, which will educate clients about employment, legal, psychiatric, relapse prevention, medical, and family issues, as well as include resources and strategies for counselors.
By linking learning modules to client results on the ASI-MV, an online interactive version of the ASI administered in treatment settings, we will be able to offer clients important tools to address key recovery issues and encourage counselors to make appropriate referrals to medical and psychosocial services.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Substance abuse research indicates that: (1) addressing medical and psychosocial problems associated with substance abuse and dependence leads to better outcomes; (2) treatments are now shorter due in part to rising healthcare costs, and it is difficult to address these issues effectively during treatment, making medical and psychosocial ("wraparound") services following treatment essential; (3) counselors may lack the knowledge to effectively integrate these services; and (4) referrals to these services have been underutilized and clients may lack the motivation, knowledge, or skills to follow up with the referrals when they are made.
To address these deficits, we are proposing the development of ASI-MV Solutions, which will provide tailored motivational feedback and skill-building lessons to clients to address specific psychosocial and medical problem areas.
We expect that ASI-MV Solutions will have seven modules (Alcohol, Drugs, Medical, Psychiatric, Legal, Employment, and Family) corresponding to domains of the ASI-MV, a Web-enabled interactive version of the ASI administered in treatment settings.
Substance abusers who have high severity scores on ASI-MV subscales will be directed to corresponding interactive lessons and local resources on ASI-MV Solutions.
To demonstrate the feasibility of the program concept, the Phase I study focused on the Employment domain.
All feasibility criteria were met and findings indicated: (1) Proposed content was based on highly positive findings from concept mapping, as well as usability and acceptance testing with clients and experts.
Ratings of potential effectiveness and appeal were high.
(2) Usability testing indicated that the program was usable by the target audience, the skills and outcomes were relevant to the target audience, and the program was regarded as potentially very helpful to the treatment process.
We surpassed feasibility benchmarks for both clients and experts.
(3) Our technical/design team produced a demonstration program that was perceived by key stakeholders as highly usable and engaging multimedia program, as well as determining the necessary technologies to produce the complete program in Phase II.
In Phase II we will develop ASI-MV Solutions content, complete the ASI-MV Solutions program, field test the program, and conduct satisfaction and acceptance testing of the program with clients and counselors.
Tipo de estudo
Intervencional
Inscrição (Real)
39
Estágio
- Fase 2
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Client Inclusion Criteria. We will recruit participants in the same proportions as in usability testing - 40% female, 40% minorities. The inclusion criteria for clients are the same as those for usability testing, except that we will require the participant to provide: (1) the names of at least three contacts who can help locate the client during the study, and (2) multiple means of contacting them (telephone, mail, and/or email). As with usability participants, we will seek clients who are in the early stages of treatment (30 days or less, including new intakes).
Exclusion Criteria:
- None
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: ASI-MV Solutions
The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions.
The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
|
The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions.
The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
|
Sem intervenção: Treatment as Usual
The Control group participants will complete the ASI-MV and receive their normal course of treatment.
The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
improved outcomes, as measured by substance use, psychosocial, and psychological functioning
Prazo: baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Addiction Severity Index - Multimedia Version (ASI-MV)
|
baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
greater problem-services matching, as measured by the number and fit of referred/received services
Prazo: baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Treatment Services Checklist (Client Version) and Treatment Services Checklist (Counselor Version).
|
baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
greater treatment motivation
Prazo: baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES, Version 8D; Miller & Tonigan, 1996)
|
baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
greater self-efficacy in managing psychosocial issues
Prazo: baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Drug Avoidance Self-Efficacy Scale
|
baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
treatment compliance
Prazo: baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Treatment Compliance: We will ask counselors to record scheduled and planned sessions within the treatment facility as a way of assessing treatment compliance.
We will also ask counselors to record client reasons for leaving treatment prematurely (Against Medical Advice, moving, hospitalization, etc.).
|
baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
treatment alliance with counselors
Prazo: baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Working Alliance Inventory-Short Form (Clients) and Working Alliance Inventory-Short Form (Counselors)
|
baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Emil Chiauzzi, PhD, Inflexxion, Inc.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de julho de 2010
Conclusão Primária (Real)
1 de julho de 2013
Conclusão do estudo (Real)
1 de julho de 2013
Datas de inscrição no estudo
Enviado pela primeira vez
27 de julho de 2010
Enviado pela primeira vez que atendeu aos critérios de CQ
20 de setembro de 2013
Primeira postagem (Estimativa)
23 de setembro de 2013
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
23 de setembro de 2013
Última atualização enviada que atendeu aos critérios de controle de qualidade
20 de setembro de 2013
Última verificação
1 de setembro de 2013
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2R44DA026232-02 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em ASI-MV Solutions
-
University of ManitobaSt. Boniface Hospital; Arterial Stiffness IncorporatedRescindidoDoença arterial coronária | Saudável | Obesidade | Doença arterial periférica | Diabetes tipo 2Canadá
-
Royal Marsden NHS Foundation TrustImperial College London; Institute of Cancer Research, United Kingdom; RM Partners...RecrutamentoFumar | Alcoolismo | Doenças Urológicas | Hipertensão | Diabetes | Câncer de próstata | Câncer de bexiga | Câncer Renal | Câncer Urológico | Problema de saúde mental | Câncer de testículoReino Unido
-
Rutgers, The State University of New JerseyRecrutamentoDepressão | Transtorno do Espectro Autista | Autismo | Transtorno do Espectro Autista com Linguagem Funcional PrejudicadaEstados Unidos
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)ConcluídoChikungunyaPorto Rico
-
Bandim Health ProjectAarhus University Hospital; Rigshospitalet, DenmarkConcluídoMortalidade | Hospitalização | Eventos adversosGuiné-Bissau
-
Themis Bioscience GmbHConcluídoInfecção pelo Vírus ChikungunyaReino Unido
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Concluído
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)ConcluídoInfecção pelo Vírus ChikungunyaPorto Rico
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...ConcluídoMeduloblastoma recorrente | Tumor Teratoide/Rabdoide Atípico | Meduloblastoma, Infância, RecorrenteEstados Unidos
-
Uppsala UniversityUppsala University HospitalRescindidoValidação do formulário ASI-SR em uma população de pacientes com dor crônica não oncológica (ASI-SR)Qualidade de vida | Dor crônica | Transtorno do uso de opioides | Redução de risco | Avaliação, AutoSuécia